Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | SCN1A | P35498 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9917383 | 0.94 | HRH3 (0.51) | ALDH1A1SMN1; SMN2KEAP1MEN1NPC1 | |
| SCHEMBL20328708 | 0.88 | MAPK1 (0.46) | ALDH1A1SMN1; SMN2KEAP1KDM4EMAPK1 | |
| SCHEMBL20328707 | 0.88 | TSHR (0.43) | ALDH1A1SMN1; SMN2KEAP1MEN1NPC1 | |
| SCHEMBL4104702 | 0.86 | MEN1 (0.43) | ALDH1A1SMN1; SMN2KEAP1MEN1KMT2A | |
| SCHEMBL13222786 | 0.86 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2KEAP1MEN1NPC1 | |
| SCHEMBL20328722 | 0.85 | PAOX (0.51) | ALDH1A1SMN1; SMN2KEAP1KDM4EMAPK1 | |
| SCHEMBL22861372 | 0.84 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2KEAP1MEN1NPC1 | |
| SCHEMBL20328698 | 0.84 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2KEAP1KDM4EMAPK1 | |
| SCHEMBL20328738 | 0.84 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2KEAP1MEN1NPC1 | |
| SCHEMBL13066033 | 0.84 | TSHR (0.49) | ALDH1A1SMN1; SMN2KEAP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4272825-A2 | MTORC MODULATORS AND USES THEREOF | Aeovian Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230331737-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331737-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11702429-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702429-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230013344-A1 | MTORC MODULATORS AND USES THEREOF | EVOTEC (FRANCE) SAS (FR) | 2023-01-19 | — | — | US | disclosed |
| US-20220267352-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2022-08-25 | — | — | US | disclosed |
| US-11230557-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| WO-2021195599-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| US-11021492-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-8044213-B2 | Thiazolyl-benzimidazoles | HOFFMANN-LA ROCHE INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20110008284-A1 | NOVEL CLYCLOSPORIN ANALOGUES | ENANTA PHARMACEUTICALS, INC. | 2011-01-13 | — | — | US | disclosed |
| US-20110008284-A1 | NOVEL CLYCLOSPORIN ANALOGUES | ENANTA PHARMACEUTICALS, INC. | 2011-01-13 | — | — | US | disclosed |
| US-20100209390-A1 | CYCLOSPORIN ANALOGUES | ENANTA PHARMACEUTICALS, INC. | 2010-08-19 | — | — | US | disclosed |
| US-7771742-B2 | Producing eye insertable drug delivery agent; extruding active ingredient with polyvinyl alcohol free biodegradable polymer; pharmacokinetics | ALLERGAN, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20100160308-A1 | Thiazolyl-Benzimidazoles | CAI JIANPING | 2010-06-24 | — | — | US | disclosed |
| US-20080260803-A1 | Producing eye insertable drug delivery agent; extruding active ingredient with polyvinyl alcohol free biodegradable polymer | ALLERGAN,INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080254096-A1 | Using polyvinyl alcohol free biodegradable polymer matrix; reducing side effects, invasive procedures and high transient concentrations; glaucoma, proliferative vitreoretinopathy | ALLERGAN,INC (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080241252-A1 | METHODS AND COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION TO TREAT OCULAR CONDITIONS | ALLERGAN, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-7414054-B2 | 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2008-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110008284-A1 | NOVEL CLYCLOSPORIN ANALOGUES | CHP1, FKBP1B, FKBP1A | ALDH1A1 4167/4885SMN1; SMN2 4751/4885KEAP1 2343/4885 |
| US-20220267352-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | RICTOR, MTOR, RPTOR | ALDH1A1 4627/4885SMN1; SMN2 2228/4885KEAP1 1760/4885 |
| US-11702429-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | ALDH1A1 4766/4885SMN1; SMN2 2851/4885KEAP1 2097/4885 |
| US-11230557-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | ALDH1A1 4766/4885SMN1; SMN2 2851/4885KEAP1 2097/4885 |
| US-20230331737-A1 | MTORC1 MODULATORS AND USES THEREOF | MTOR, RPTOR, RICTOR | ALDH1A1 4764/4885SMN1; SMN2 1159/4885KEAP1 1931/4885 |
| US-20230013344-A1 | MTORC MODULATORS AND USES THEREOF | MTOR, RICTOR, RPTOR | ALDH1A1 4766/4885SMN1; SMN2 2851/4885KEAP1 2097/4885 |
| US-20100209390-A1 | CYCLOSPORIN ANALOGUES | HAVCR2, CHP1, ICOS | ALDH1A1 2724/4885SMN1; SMN2 4414/4885KEAP1 1590/4885 |
| US-20080254096-A1 | Using polyvinyl alcohol free biodegradable polymer matrix; reducing side effects, invasive procedures and high transient concentrations; glaucoma, proliferative vitreoretinopathy | VEGFA, PTK2, KDR | ALDH1A1 1521/4885SMN1; SMN2 4227/4885KEAP1 3932/4885 |
| US-20080241252-A1 | METHODS AND COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION TO TREAT OCULAR CONDITIONS | FLT1, JAK1, KDR | ALDH1A1 4379/4885SMN1; SMN2 2992/4885KEAP1 2155/4885 |
| US-20100160308-A1 | Thiazolyl-Benzimidazoles | CYP3A7, CYP2C19, CYP3A5 | ALDH1A1 100/4885SMN1; SMN2 2260/4885KEAP1 2289/4885 |
| US-11021492-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | ALDH1A1 4766/4885SMN1; SMN2 2851/4885KEAP1 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.